Copernicus Capital Management’s ProQR Therapeutics PRQR Stock Holding History

Copernicus Capital Management’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$335K	Buy	+40,000	New	+$261K	4.05%	11

Other funds holding PRQR

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Copernicus Capital Management's PRQR Position: Q3 2021 in Review

Copernicus Capital Management opened a new position in ProQR Therapeutics (PRQR) in Q3 2021: 40,000 shares worth $335K. The stake represents 4.05% of the portfolio and ranks #11 among its holdings.

67 funds tracked by Wall St. Rank hold PRQR as of Q3 2021.

Copernicus Capital Management held 40,000 shares of ProQR Therapeutics worth $335K as of Q3 2021.
ProQR Therapeutics was a new Copernicus Capital Management position in Q3 2021.
ProQR Therapeutics made up 4.05% of Copernicus Capital Management's portfolio in Q3 2021, its #11 holding.
67 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q3 2021.

Based on Copernicus Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.